US Stock Insider Trading | Tactile Systems disclosed 6 insider transactions on February 24

K-LinePoet · 2026-03-05T21:26:42+00:00

On February 24, 2026, Tactile Systems disclosed multiple insider transactions, including Director Dodd Sheri Louise selling 14,700 shares for a total of $415,800. The company focuses on developing home therapy devices aimed at improving treatment standards and quality of life for chronic diseases.

K-LinePoet

2026-03-05 21:26:42

Abstract generation in progress

On February 24, 2026, Tactile Systems (TCMD) disclosed six insider transactions. Director Dodd Sheri Louise sold 14,700 shares on February 23, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Director	Dodd Sheri Louise	February 23, 2026	Sell	537	28.69	15,400
February 24, 2026	Executive	Burns Kristie	February 23, 2026	Sell	160	28.69	4,590.29
February 24, 2026	Executive	Birkemeyer Elaine M.	February 23, 2026	Sell	5,322	28.28	150,500
February 24, 2026	Director	Dodd Sheri Louise	February 23, 2026	Sell	14,700	28.28	415,800
February 24, 2026	Executive	Birkemeyer Elaine M.	February 23, 2026	Sell	196	28.69	5,623.08
February 24, 2026	Executive	Burns Kristie	February 23, 2026	Sell	4,279	28.28	121,000
January 6, 2026	Executive	Burns Kristie	January 2, 2026	Sell	5,139	28.85	148,300
May 14, 2025	Executive	Birkemeyer Elaine M.	May 12, 2025	Sell	2,921	9.94	29,000
May 12, 2025	Director	Dodd Sheri Louise	May 8, 2025	Sell	3,149	9.83	31,000
May 9, 2025	Director	WILLIAM W BURKE	May 8, 2025	Sell	3,300	9.67	31,900

[Company Profile]

Tactile Systems Technology, Inc. was founded on January 30, 1995. The company develops and sells home therapy devices for treating chronic diseases. They focus on improving the standards of home therapy for chronic conditions, enhancing treatment effectiveness and quality of life, and helping to control healthcare costs. They own a proprietary and scalable platform that provides home therapy solutions across the United States. This evolving medical approach is increasingly recognized by the government and taxpayers as a key method to curb rising healthcare expenses. Their initial treatment focus was on vascular diseases, aiming to improve home therapy standards for lymphedema and chronic venous insufficiency. Their main products include the Flexitouch System for home treatment of lymphedema and the ACTitouch System, a wearable therapy device for patients with chronic venous insufficiency.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes